The predominance of ASCL1-high cells in chemotherapy-sensitive samples suggests that this subtype may possess metabolic vulnerabilities that could be therapeutically exploited, consistent with findings by Redin et al. (2024), who identified subtype-specific metabolic targets in SCLC. The gene discussed is ASCL1; the disease is small cell lung carcinoma.